The business model of a US health insurer in this situation frankly sucks, however. If Clover successfully manages a reversion outcome with aggressive short-term techniques for a chronic condition, then nothing prevents the patient from switching away to a cheaper insurer afterwards. Clover puts in all the hard work, and another insurer reaps the actuarial benefits. That has to be fixed, because all the big killers of patients, insurer profits and medical budgets in the developed nations are the biological analogs of Advanced Persistent Threats, and not amenable to fixes developed for acute situations (which as a civilization we're really good at addressing).

That's a big "if" for a Medicare Advantage insurer, since we can't enroll someone unless they're eligible for Medicare. Although it's possible to become Medicare-eligible prior to age 65, it's much less common, and some of the ways it happens make someone ineligible to enroll in a Medicare Advantage plan (for example, someone with end-stage renal disease is Medicare-eligible regardless of age, but unless already enrolled in one cannot join a Medicare Advantage plan -- they must opt for traditional Medicare instead).

So by the time a typical diabetic becomes eligible for a Medicare Advantage plan, the intense regimes you're talking about don't (as far as I know) offer any realistic chance of reverting. Which means most of the effort instead goes into proper management techniques to prevent progression and complications.